Cytochrome P-450 CYP3A4 Inducers (weak)

DrugDrug NameDrug Indication
DB06413ArmodafinilInvestigated for use/treatment in sleep disorders, obstructive sleep apnea, schizophrenia and schizoaffective disorders, depression, and bipolar disorders.
DB08909Glycerol phenylbutyrateGlycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
DB11586AsunaprevirAsunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
DB00615RifabutinFor the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
DB06201RufinamideAdjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
DB04911OritavancinIndicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
DB00349ClobazamFor treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
DB00949FelbamateFor use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
DB09119Eslicarbazepine acetateEslicarbazepine acetate is indicated as adjunctive therapy in the treatment of partial-onset seizures that are not adequately controlled with conventional therapy in epileptic patients.
DB01645GenisteinCurrently Genistein is being studied in clinical trials as a treatment for prostate cancer.
DB09078LenvatinibLenvatinib is indicated for the treatment of following conditions. - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. - First-line treatment of unresectable hepatocellular carcinoma (HCC).
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB11767SarilumabIndicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate.
DB09036SiltuximabSiltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
DB14575EslicarbazepineNot Available
DB00273TopiramateTopiramate is indicated for the following conditions: - Monotherapy for partial onset or primary generalized tonic-clonic seizures in patients over 2 years of age. - Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for adult and pediatric patients. - Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients over 2 years of age. - Prophylaxis of migraine headache in adults.[FDA label] A seizure is an abnormal, unregulated electrical discharge occurring in the brain's cortical gray matter. This electrical response produces a transient interruption in the normal brain function which in order produces altered awareness, abnormal sensations, focal involuntary movements or convulsions. The type of seizure can be classified according to the type of onset followed by a type of seizure.[L5548] A migraine headache is a [ulsating or throbbing pain that can be presented in one of both sides of the head and it can be worsened by external stimuli such as physical activity, light, sounds, and odors.[L5551] Topiramate has been commonly investigated and used off-label for weight reduction in patients with obesity or diabetes.[A175240]
DB11823EsketamineThis drug is indicated in conjunction with an oral antidepressant for the treatment of treatment-resistant depression (TRD) in adults [FDA label]. Note: Esketamine is not approved as an anesthetic agent. The safety and effectiveness of esketamine as an anesthetic agent have not been established to this date [FDA label].
DB00682Warfarin**Indicated** for:[label,L6616] 1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism. 2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation. 3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement. 4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction. **Off-label** uses include: 1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]
DB12015AlpelisibAlpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer.[Label] This cancer must be hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and PIK3CA­ mutated.[Label] The cancer must be detected by an FDA-approved test following progression on or after an endocrine-based regimen.[Label]
DB00745ModafinilTo improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
DrugDrug NameTargetType
DB06413ArmodafinilCytochrome P450 2C19enzyme
DB06413ArmodafinilCytochrome P450 3A4enzyme
DB06413ArmodafinilCytochrome P450 1A2enzyme
DB06413ArmodafinilCytochrome P450 2B6enzyme
DB06413ArmodafinilCytochrome P450 3A5enzyme
DB06413ArmodafinilCytochrome P450 2C9enzyme
DB06413ArmodafinilSodium-dependent dopamine transportertarget
DB08909Glycerol phenylbutyratePancreatic triacylglycerol lipaseenzyme
DB08909Glycerol phenylbutyrateCytochrome P450 3A4enzyme
DB08909Glycerol phenylbutyrateCytochrome P450 2D6enzyme
DB11586AsunaprevirHepatitis C virus NS3 protease/helicasetarget
DB11586AsunaprevirMultidrug resistance protein 1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1carrier
DB11586AsunaprevirCytochrome P450 3A4enzyme
DB11586AsunaprevirCytochrome P450 3A5enzyme
DB11586AsunaprevirCytochrome P450 2A6enzyme
DB11586AsunaprevirCytochrome P450 2B6enzyme
DB11586AsunaprevirCytochrome P450 2C9enzyme
DB11586AsunaprevirCytochrome P450 2C19enzyme
DB11586AsunaprevirCytochrome P450 2D6enzyme
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B3transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1transporter
DB00615RifabutinDNA-directed RNA polymerase subunit alphatarget
DB00615RifabutinHeat shock protein HSP 90-alphatarget
DB00615RifabutinCytochrome P450 3A4enzyme
DB00615RifabutinDNA-directed RNA polymerase subunit betatarget
DB00615RifabutinDNA-directed RNA polymerase subunit beta'target
DB00615RifabutinCytochrome P450 2C19enzyme
DB00615RifabutinCytochrome P450 2B6enzyme
DB00615RifabutinCytochrome P450 2C8enzyme
DB00615RifabutinCytochrome P450 2C9enzyme
DB00615RifabutinCytochrome P450 2D6enzyme
DB00615RifabutinMultidrug resistance protein 1transporter
DB06201RufinamideMetabotropic glutamate receptor 5target
DB06201RufinamideLiver carboxylesterase 1enzyme
DB06201RufinamideSodium channel protein type 9 subunit alphatarget
DB06201RufinamideSerum albumincarrier
DB06201RufinamideCytochrome P450 2E1enzyme
DB06201RufinamideCytochrome P450 3A4enzyme
DB04911OritavancinCytochrome P450 3A4enzyme
DB04911OritavancinCytochrome P450 2D6enzyme
DB04911OritavancinCytochrome P450 2C9enzyme
DB04911OritavancinCytochrome P450 2C19enzyme
DB00349ClobazamCytochrome P450 2C19enzyme
DB00349ClobazamCytochrome P450 3A4enzyme
DB00349ClobazamCytochrome P450 2B6enzyme
DB00349ClobazamCytochrome P450 2C18enzyme
DB00349ClobazamSodium- and chloride-dependent GABA transporter 1transporter
DB00349ClobazamSodium- and chloride-dependent GABA transporter 3transporter
DB00349ClobazamMultidrug resistance protein 1transporter
DB00349ClobazamGABA-A receptor (anion channel)target
DB00349ClobazamCytochrome P450 2D6enzyme
DB00949FelbamateGlutamate receptor ionotropic, NMDA 3Atarget
DB00949FelbamateGlutamate receptor ionotropic, NMDA 2Btarget
DB00949FelbamateGlutamate receptor ionotropic, NMDA 2Atarget
DB00949FelbamateCytochrome P450 2C19enzyme
DB00949FelbamateCytochrome P450 3A4enzyme
DB00949FelbamateCytochrome P450 2E1enzyme
DB00949FelbamateCytochrome P450 2C9enzyme
DB09119Eslicarbazepine acetateCytochrome P450 2C19enzyme
DB09119Eslicarbazepine acetateCytochrome P450 3A4enzyme
DB09119Eslicarbazepine acetateP2X purinoceptor 4target
DB09119Eslicarbazepine acetateUDP-glucuronosyltransferase 1-1enzyme
DB01645GenisteinEstrogen receptor betatarget
DB01645GenisteinDNA topoisomerase 2-alphatarget
DB01645GenisteinProtein-tyrosine kinase 2-betatarget
DB01645GenisteinMultidrug resistance protein 1transporter
DB01645GenisteinMultidrug resistance-associated protein 1transporter
DB01645GenisteinATP-binding cassette sub-family G member 2transporter
DB01645GenisteinCytochrome P450 1A2enzyme
DB01645GenisteinNuclear receptor coactivator 1target
DB01645GenisteinEstrogen receptor alphatarget
DB01645GenisteinNuclear receptor coactivator 2target
DB01645GenisteinSteroid hormone receptor ERR2target
DB01645GenisteinSteroid hormone receptor ERR1target
DB01645GenisteinNuclear receptor subfamily 1 group I member 2target
DB01645GenisteinRAC-alpha serine/threonine-protein kinasetarget
DB01645GenisteinG-protein coupled estrogen receptor 1target
DB01645GenisteinCytochrome P450 1B1target
DB01645GenisteinSex hormone-binding globulintarget
DB01645GenisteinCytochrome P450 1A1enzyme
DB01645GenisteinSolute carrier organic anion transporter family member 1B1transporter
DB01645GenisteinSolute carrier organic anion transporter family member 2B1transporter
DB01645GenisteinCytochrome P450 2C8enzyme
DB01645GenisteinCytochrome P450 2C9enzyme
DB01645GenisteinCytochrome P450 3A1enzyme
DB01645GenisteinCytochrome P450 3A2enzyme
DB01645GenisteinCytochrome P450 3A4enzyme
DB09078LenvatinibVascular endothelial growth factor receptor 1target
DB09078LenvatinibVascular endothelial growth factor receptor 2target
DB09078LenvatinibVascular endothelial growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 1target
DB09078LenvatinibFibroblast growth factor receptor 2target
DB09078LenvatinibFibroblast growth factor receptor 3target
DB09078LenvatinibFibroblast growth factor receptor 4target
DB09078LenvatinibPlatelet derived growth factor receptor alphatarget
DB09078LenvatinibMast/stem cell growth factor receptor Kittarget
DB09078LenvatinibMultidrug resistance protein 1transporter
DB09078LenvatinibATP-binding cassette sub-family G member 2transporter
DB09078LenvatinibCytochrome P450 3A4enzyme
DB09078LenvatinibAldehyde oxidaseenzyme
DB09078LenvatinibCytochrome P450 2C8enzyme
DB09078LenvatinibCytochrome P450 2C9enzyme
DB09078LenvatinibCytochrome P450 1A2enzyme
DB09078LenvatinibCytochrome P450 2B6enzyme
DB09078LenvatinibCytochrome P450 2C19enzyme
DB09078LenvatinibSolute carrier family 22 member 6transporter
DB09078LenvatinibSolute carrier family 22 member 8transporter
DB09078LenvatinibSolute carrier family 22 member 2transporter
DB09078LenvatinibSolute carrier organic anion transporter family member 1B1transporter
DB09078LenvatinibBile salt export pumptransporter
DB09078LenvatinibCytochrome P450 2D6enzyme
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06273TocilizumabCytochrome P450 3A4enzyme
DB11767SarilumabAlanine aminotransferase 1enzyme
DB11767SarilumabAlanine aminotransferase 2enzyme
DB11767SarilumabAspartate aminotransferaseenzyme
DB11767SarilumabCytochrome P450 3A4enzyme
DB11767SarilumabInterleukin-6 receptor subunit alphatarget
DB11767SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB09036SiltuximabCytochrome P450 3A4enzyme
DB14575EslicarbazepineUDP-glucuronosyltransferase 1-1enzyme
DB14575EslicarbazepineCytochrome P450 2C19enzyme
DB14575EslicarbazepineCytochrome P450 3A4enzyme
DB14575EslicarbazepineP2X purinoceptor 4target
DB00273TopiramateGamma-aminobutyric acid receptor subunit alpha-1target
DB00273TopiramateSodium channel protein type 1 subunit alphatarget
DB00273TopiramateCarbonic anhydrase 2target
DB00273TopiramateCarbonic anhydrase 4target
DB00273TopiramateGlutamate receptor ionotropic, kainate 1target
DB00273TopiramateCytochrome P450 2C19enzyme
DB00273TopiramateCytochrome P450 3A4enzyme
DB00273TopiramateGABA-A receptor (anion channel)target
DB00273TopiramateCarbonic anhydrase 1target
DB00273TopiramateCarbonic anhydrase 3target
DB00273TopiramateGlutamate receptor 1target
DB11823EsketamineNMDA receptortarget
DB11823EsketamineCytochrome P450 2B6enzyme
DB11823EsketamineCytochrome P450 3A4enzyme
DB11823EsketamineCytochrome P450 2C19enzyme
DB11823EsketamineCytochrome P450 2C9enzyme
DB11823EsketamineSodium-dependent dopamine transportertransporter
DB11823EsketamineSodium hydroxidecarrier
DB11823EsketamineEdetate disodiumcarrier
DB11823EsketamineCitric acid monohydratecarrier
DB11823EsketamineGlutamate receptor ionotropic, NMDA 2Btarget
DB11823EsketamineElongation factor 2target
DB11823EsketamineBrain-derived neurotrophic factortarget
DB11823EsketamineBDNF/NT-3 growth factors receptortarget
DB00682WarfarinVitamin K epoxide reductase complex subunit 1target
DB00682WarfarinCytochrome P450 2C8enzyme
DB00682WarfarinCytochrome P450 1A2enzyme
DB00682WarfarinCytochrome P450 2C9enzyme
DB00682WarfarinAlpha-1-acid glycoprotein 1carrier
DB00682WarfarinSerum albumincarrier
DB00682WarfarinCytochrome P450 2C19enzyme
DB00682WarfarinCytochrome P450 3A4enzyme
DB00682WarfarinCytochrome P450 2C18enzyme
DB00682WarfarinNuclear receptor subfamily 1 group I member 2target
DB12015AlpelisibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformtarget
DB12015AlpelisibCytochrome P450 3A4enzyme
DB12015AlpelisibCytochrome P450 2C9enzyme
DB12015AlpelisibCytochrome P450 2C8enzyme
DB12015AlpelisibCytochrome P450 2C19enzyme
DB12015AlpelisibATP-binding cassette sub-family G member 2transporter
DB12015AlpelisibMultidrug resistance protein 1transporter
DB00745ModafinilSodium-dependent dopamine transportertarget
DB00745ModafinilAlpha-1B adrenergic receptortarget
DB00745ModafinilCytochrome P450 3A4enzyme
DB00745ModafinilCytochrome P450 2C19enzyme
DB00745ModafinilCytochrome P450 1A2enzyme
DB00745ModafinilCytochrome P450 2B6enzyme
DB00745ModafinilCytochrome P450 2C9enzyme
DB00745ModafinilCytochrome P450 3A5enzyme